Skip to contentC
CV Sciences, Inc.
C
CVSICV Sciences, Inc. Q2 2026 · 10-Q
Revenue$2.99M$2.99M−17.5% vs Q2 2025 Net Income-$775.00K-$775.00KN/M vs Q2 2025 EPS Diluted$0.00$0.00— vs Q2 2025 Gross Profit$1,450,000−21.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CV Sciences, Inc. · CIK 1510964 · Engraved from SEC EDGAR
Operating Cash Flowderived$20,000−93.0% Free Cash Flowderived$13,000−94.5% Margins · derivedGross margin48.6%−2.4 pt vs Q2 2025
Operating margin-10.1%−6.5 pt vs Q2 2025
Net margin-26.0%−18.8 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 13, 2026 · 44 d after period end